Kyowa Kirin’s NOURIANZ™ bags FDA nod for sale in the U.S.
Category: #health  By Mateen Dalal  Date: 2019-10-16
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Kyowa Kirin’s NOURIANZ™ bags FDA nod for sale in the U.S.

Parkinson’s Disease is a progressive nervous system disorder that hampers the movement of the body by causing stiffness or slowness. Currently there are no definitive treatments for this clinical condition. However, various pharmaceutical firms are constantly working on developing a definitive treatment which could completely treat Parkinson’s disease.

Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd., recently made some advancements as it announced that the firm’s latest treatment named NOURIANZ™ for levodopa/carbidopa in the grownup subjects who experience “off” episodes due to Parkinson’s disease (PD) will be accessible in the U.S.

For the uninitiated, an “off” episode occurs when the PD’s symptoms such as motor fluctuations re-emerge during an on-going treatment.

Speaking on the announcement, Tom Stratford, President, Kyowa Kirin USA Holdings, Inc., said that the company is pleased to provide NOURIANZ, a unique and exclusive adenosine A2A receptor antagonist treatment cleared by the FDA for ‘off’ experiences faced during the treatment of PD.

Sources cite that the FDA had based their approval on the results provided from the multicenter, randomized, placebo-controlled, double-blind trials in patients suffering from PD while being on a steady dosage of levodopa/carbidopa.

As for Rachel Dolhun, M.D., Vice President, Medical Communications, Michael J. Fox Foundation, treatments like NOURIANZ will hugely be beneficial for a PD patient going through an ‘off’ episodes, which sometimes could be isolating and troublesome for people with Parkinson's and their families.

Dolhun further added that the foundation urges patients to discuss their ‘off” episodes with their healthcare providers.

Reportedly, in 2019, Kyowa Hakko Kirin Co., Ltd. also made headlines when it presented its post-hoc analysis of MAVORIC studies at the 2019 Annual Meeting of the ASCO (American Society of Clinical Oncology).

As per reports, the trial was for cutaneous T-cell lymphoma, a rare type of cancer that begins in WBCs called T cells, in which patients with previously treated SS (Sézary syndrome)and MF (mycosis fungoides) were randomized to either mogamulizumab or vorinostat.

Source Credit: https://www.businesswire.com/news/home/20191014005706/en/Kyowa-Kirin-Announces-NOURIANZ%E2%84%A2-Istradefylline-U.S.-Treatment

 

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal     twitter

Mateen Dalal

A qualified electronics and telecommunication engineer, Mateen Dalal embarked on his professional journey working as a quality and test engineer. Harnessing his passion for content creation however, Mateen pens down industry-rich articles for ReportsGO.com and a few o...

Read More..

More News By Mateen Dalal

China unveils plans to reinforce stringent safety standards for EVs

China unveils plans to reinforce stringent safety standards for EVs

By Mateen Dalal

This news comes amid rising incidences of battery fires and breaks failures. China will require automakers to have a 24-hour emergency response system to address major accidents. China is planning to reinforce strict safety standards for electri...

Facebook testing new option for cross-posting content to Instagram

Facebook testing new option for cross-posting content to Instagram

By Mateen Dalal

Facebook, Inc is reportedly testing an option that will allow users to cross-post their photos, videos, and other posts on their Instagram. It already has the feature to let people cross-post their Instagram content to Facebook. This upcoming featur...

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

General Motors to recoup USD 1.9 Bn from LG spent on Bolt EV recall

By Mateen Dalal

GM will recover almost all the costs from the recall of its Bolt EV models. Despite the EV battery manufacturing mishap from LG, the two companies will continue to work together. General Motors (GM) has agreed to recover around USD 1.9 billion f...